Absci Co. (NASDAQ:ABSI) Stock Holdings Lifted by Barclays PLC

Barclays PLC lifted its stake in shares of Absci Co. (NASDAQ:ABSI) by 379.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 131,504 shares of the company’s stock after acquiring an additional 104,083 shares during the quarter. Barclays PLC’s holdings in Absci were worth $503,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ABSI. FMR LLC boosted its stake in shares of Absci by 1.2% during the 3rd quarter. FMR LLC now owns 12,727,760 shares of the company’s stock valued at $48,620,000 after buying an additional 147,156 shares during the period. Fred Alger Management LLC grew its position in Absci by 4.3% in the 3rd quarter. Fred Alger Management LLC now owns 7,566,618 shares of the company’s stock worth $28,904,000 after purchasing an additional 309,843 shares during the last quarter. ARK Investment Management LLC lifted its position in shares of Absci by 15.1% in the 3rd quarter. ARK Investment Management LLC now owns 6,337,622 shares of the company’s stock worth $24,210,000 after acquiring an additional 833,734 shares during the period. Marshall Wace LLP increased its holdings in Absci by 23.3% in the 2nd quarter. Marshall Wace LLP now owns 1,833,902 shares of the company’s stock valued at $5,648,000 after buying an additional 347,079 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in Absci by 21.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 889,844 shares of the company’s stock valued at $3,399,000 after purchasing an additional 158,086 shares in the last quarter. 52.05% of the stock is currently owned by institutional investors and hedge funds.

Absci Stock Performance

ABSI stock opened at $2.71 on Friday. The firm has a market cap of $311.26 million, a PE ratio of -2.91 and a beta of 2.02. Absci Co. has a 1-year low of $2.45 and a 1-year high of $6.72. The stock has a 50-day moving average price of $3.30 and a 200-day moving average price of $3.68. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01.

Absci (NASDAQ:ABSI) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05). The firm had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $1.77 million. Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%. During the same period in the prior year, the firm earned ($0.24) earnings per share. As a group, equities research analysts expect that Absci Co. will post -0.9 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Guggenheim reiterated a “buy” rating and set a $10.00 price target on shares of Absci in a research report on Tuesday, December 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Absci in a research note on Friday, December 13th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Absci has a consensus rating of “Buy” and an average price target of $8.67.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.